ABSTRACT
Venous thromboembolism (VTE) is a main contributor to morbidity and mortality in cancer patients. Biomarkers with the potential to predict cancer-associated VTE are continually sought. Of these, markers of thrombin generation present a likely option. The present systematic review examines the ability of three widely used biomarkers of thrombin generation: prothrombin fragment 1.2 (F1.2), thrombin-antithrombin complex (TAT), and ex vivo thrombin generation, to predict VTE in both solid and hematologic adult cancer patients. Relevant studies were identified in the PubMed and Embase databases, and the review conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Each study was evaluated using the quality assessment tool from the National Heart, Lung, and Blood Institute. The review protocol was published on PROSPERO with identifier CRD42022362339. In total, 24 papers were included in the review: 11 reporting data on F1.2, 9 on TAT, and 12 on ex vivo thrombin generation. The quality ratings of the included studies varied from good (n = 13), fair (n = 8), to poor (n = 3) with a high heterogenicity. However, F1.2, TAT complex, and ex vivo thrombin generation were all found to be associated with the development of VTE. This association was most pronounced for F1.2. Furthermore, the determination of F1.2 was able to improve the precision of several established risk assessment scores. In conclusion, markers of thrombin generation were found to be elevated in cancer patients with VTE, and particularly, F1.2 was found to be a promising predictor of cancer-associated VTE.
PMID:37813372 | DOI:10.1055/s-0043-1775856
12:58
PubMed articles on: Cardio-Oncology
Social disparities in cardiovascular mortality of patients with cancer in the USA between 1999 and 2019
12:58
PubMed articles on: Cardio-Oncology
Multimodal Imaging of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer-A State-of-the-Art Review
12:58
PubMed articles on: Cancer & VTE/PE
Episodic Cocaine Use as a Cause of Venous Thromboembolism and Acute Liver Injury
12:58
PubMed articles on: Cardio-Oncology
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
12:58
PubMed articles on: Cancer & VTE/PE
Risk factors for bleeding in cancer patients treated with conventional dose followed by low dose apixaban for venous thromboembolism
Thromb Haemost. 2023 Oct 10. doi: 10.1
No comments:
Post a Comment
اكتب تعليق حول الموضوع